Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis

Laboratory Investigation

Volumn 74, Issue 6, 1996, Pages 1039-1049

  Gorter, Arko ^a   Blok, Vanessa T ^a   Haasnoot, Willem H B ^a   Ensink, N Geeske ^a   Daha, Mohamed R ^a   Fleuren, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CHROMIUM 51; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; MEMBRANE BINDING; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT PATHWAY, CLASSICAL; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIUM; HUMANS; KIDNEY NEOPLASMS; KIDNEY TUBULES, PROXIMAL; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; TUMOR CELLS, CULTURED;

EID: 0029898496     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr, Oettgen HF, Melamed MR, and Old LJ (1989). Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 49: 6774-6780.
2. Bjørge L, Vedeler CA, Ulvestad E, and Matre R (1994). Expression and function of CD59 on colonie adenocarcinoma cells. Eur J Immunol 24:1597-1603.
3. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, and Maio M (1995). Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 61:548-556.
4. Brooimans RA, Stegmann APA, van Dorp WT, van der Ark AAJ, van der Woude FJ, van Es LA, and Daha MR (1991). Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J Clin Invest 88:379-384.
5. Brooimans RA, van Wieringen PAM, van Es LA, and Daha MR (1992). Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis. Eur J Immunol 22; 3135-3140.
6. Chang C-P, Hüsler T, Zhao J, Wiedmer T, and Sims PJ (1994). Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59. J Biol Chem 269:26424-26430.
7. Cheung N-KV, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, and Medof ME (1988). Decay-accelerating factor protects human tumor cells from complementmediated cytotoxicity in vitro. J Clin Invest 81:1122-1128.
8. Cho SW, Oglesby TJ, Hsi B-L, Adams EM, and Atkinson JP (1991). Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay. Clin Exp Immunol 83:257-261.
9. Cooke JM, Fischer E, Boucheix C, Mirsrahi M, Jouvin MH, Weiss L, Jack RM, and Kazachkine MD (1985). Mouse monoclonal antibodies to the human C3b receptor. Mol Immunol 22:531-539.
10. Corver WE, Cornelisse CJ, Hermans J, and Fleuren GJ (1995). Limited loss of nine tumor-associated surface antigenic determinants after tryptic cell dissociation. Cytometry 19:267-272.
11. Cosio FG, Shibata T, Rovin BH, and Birmingham DJ (1994). Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. Kidney Int 46:986-992.
12. Coyne KE, Hall SE, Thompson ES, Arce MA, Kinoshita T, Fujita T, Anstee DJ, Rosse W, and Lublin DM (1992). Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 149:2906-2913.
13. Detrisac JC, Sens MA, Garvin AJ, Spicer SS, and Sens DA (1984). Tissue culture of human kidney epithelial cells of proximale tubule origin. Kidney Int 25:383-390.
14. Dijk J Van, Warnaar SO, Eendenburg JDH van, Thienpont M, Braakman E, Boot JHA, Fleuren GJ, and Bolhuis RLH (1989). Induction of tumor cell lysis by bispecific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen. Int J Cancer 43:344-349.
15. Dillman RO (1994). Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515.
16. Dippold W and Bernhard H (1992). Immunorecognition of ganglioside epitopes: Correlation between affinity and cytotoxicity of ganglioside antibodies. Eur J Cancer 28A:1605-1610.
17. Edwards DP, Grzyb KT, Dressler LG, Mansel RE, Zava DT, Sledge GW Jr, and McGuire WL (1986). Monoclonal antibody identification and characterization of a Mr 43:000 membrane glycoprotein associated with human breast cancer. Cancer Res 46: 1306-1317.
18. Fearon DT (1984). Cellular receptors for fragments of the third component of complement. Immunol Today 5:105-110.
19. Fletcher A, Bryant JA, Gardner B, Judson PA, Spring FA, Parsons SF, Mallinson G, and Anstee DJ (1992). New monoclonal antibodies in CD59: Use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 75:507-512.
20. Hakulinen J and Meri S (1994). Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 71:820-827.
21. Harris CL and Morgan BP (1995). Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells: An analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology 86:311-318.
22. Hofman P, Hsi B-L, Manie S, Fenichel P, Thyss A, and Rossi B (1994). High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: A preventive mechanism of malignant tumor cells against complement attack. Breast Cancer Res Treat 32:213-219.
23. Holthöfer H, Miettinen A, Paasivuo R, Lehto V-P, Linder E, Alfthan O, and Virtanen I (1983). Cellular origin and differentiation of renal cell carcinomas: A fluorescence microscopic study with kidney-specific antibodies, anti-intermediate filament antibodies, and lectins. Lab Invest 49:317-326.
24. Hsi BL, Yeh C-JG, Fenichel P, Samson M, and Griveaux C (1988). Monoclonal antibody GB24 recognizes a trophoblast-lymphocyte cross-reactive antigen. Am J Reprod Microbiol Immunol 18:21-27.
25. Hüsler T, Lockert DH, Kaufman KM, Sodetz JM, and Sims PJ (1995). Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59. J Biol Chem 270:3483-3486.
26. Ichida S, Yuzawa Y, Okada H, Yoshioka K, and Matsuo S (1994). Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46:89-96.
27. Junnikkala S, Hakulinen J, and Meri S (1994). Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol 24:611-615.
28. Kumar S, Vinci JM, Pytel BA, and Baglioni C (1993). Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 53:348-353.
29. Lockert DH, Kaufman KM, Chang CP, Hüsler T, Sodetz JM, and Sims PJ (1995). Identity of the segment of human complement C8 recognized by complement regulatory protein CD59. J Biol Chem 270:19723-19728.
30. Medof ME, Kinoshita T, and Nussenzweig V. (1984a). Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558-1578.
31. Medof ME, Walter EI, Rutgers JL, Knowles DM, and Nussenzweig V (1984b). Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165: 848-864.
32. Morgan BP (1992). Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 178:115-140.
33. Morgan BP and Meri S (1994). Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15:369-396.
34. Ollert MW, Kadlec JV, Petrella EC, Bredehorst R, and Vogel C-W (1993). Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65. Cancer Res 53:592-599.
35. Oosterwijk E, Debruyne FMJ, and Schalken JA (1995). The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 22:34-41.
36. Oosterwijk E, Ruiter DJ, Hoedemaeker PhJ, Pauwels EKJ, Jonas U, Zwartendijk J, and Warnaar SO (1986). Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494.
37. Pittman K and Selby P (1994). The management of renal cell carcinoma. Crit Rev Oncol Hematol 16:181-200.
38. Ratnoff WD, Knez JJ, Prince GM, Okada H, Lachmann PJ, and Medof ME (1992). Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol 87:415-421.
39. Real FX, Bander, NH, Cordon-Cardo C, Old LJ, and Oettgen HF (1988). Phase I study of monoclonal antibody F23 in patients with renal cancer. Proc Am Soc Clin Oncol 7:131.
40. Reiter Y, Ciobotariu A, and Fishelson Z (1992). Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 22:1207-1213.
41. Schönermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, and Hänsch GM (1986). Homologous species restriction in lysis of human erythrocytes: A membrane derived protein with C8-binding capacity functions as a inhibitor. J Immunol 136:1772-1776.
42. Seya T, Hara T, Matsumoto M, and Akedo H (1990). Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol 145:238-245.
43. Seya T, Turner J, and Atkinson JP (1986). Purification and characterization of a membrane protein (gp45-70) which is a cofactor for cleavage of C3b and C4b. J Exp Med 163:837-855.
44. Shibata T, Cosio FG, and Birmingham DJ (1991). Complement activation induces the expression of decay-acceleration factor on human mesangial cells. J Immunol 147:3901-3908.
45. Shibata T and Kohsaka T (1995). Effects of complement activation on the expression of CD59 by human mesangial cells. J Immunol 155:403-409.
46. Terachi T, Stanescu G, Pontes JE, Medof ME, and Caulfield MJ (1991). Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res 51:2521-2523.
47. Tomlinson S, Whitlow MB, and Nussenzweig V (1994). A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9. J Immunol 152:1927-1934.
48. Velders MP, Litvinov SV, Warnaar SO, Gorter A, Fleuren GJ, Zurawski VR Jr, and Coney LR (1994). New chimeric antipancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 54:1753-1759.
49. Walter EI, Roberts WL, Terrone R, Rosenberry L, Ratnoff WD, and Medof ME (1990). Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage. J Immunol 144:1030-1036.
50. Zalman LS, Wood LM, and Müller-Eberhard HJ (1986). Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 83:6975-6979.